Oral resveratrol reduces neuronal damage in a model of multiple sclerosis.
Publication/Presentation Date
12-1-2010
Abstract
BACKGROUND: Neuronal loss in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), correlates with permanent neurological dysfunction. Current MS therapies have limited the ability to prevent neuronal damage.
METHODS: We examined whether oral therapy with SRT501, a pharmaceutical grade formulation of resveratrol, reduces neuronal loss during relapsing-remitting EAE. Resveratrol activates SIRT1, an NAD+-dependent deacetylase that promotes mitochondrial function.
RESULTS: Oral SRT501 prevented neuronal loss during optic neuritis, an inflammatory optic nerve lesion in MS and EAE. SRT501 also suppressed neurological dysfunction during EAE remission, and spinal cords from SRT501-treated mice had significantly higher axonal density than vehicle-treated mice. Similar neuroprotection was mediated by SRT1720, another SIRT1-activating compound; and sirtinol, an SIRT1 inhibitor, attenuated SRT501 neuroprotective effects. SIRT1 activators did not prevent inflammation.
CONCLUSIONS: These studies demonstrate that SRT501 attenuates neuronal damage and neurological dysfunction in EAE by a mechanism involving SIRT1 activation. SIRT1 activators are a potential oral therapy in MS.
Volume
30
Issue
4
First Page
328
Last Page
339
ISSN
1536-5166
Published In/Presented At
Shindler, K. S., Ventura, E., Dutt, M., Elliott, P., Fitzgerald, D. C., & Rostami, A. (2010). Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 30(4), 328–339. https://doi.org/10.1097/WNO.0b013e3181f7f833
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
21107122
Department(s)
Administration and Leadership
Document Type
Article